- Home
- BBIO vs TOL Comparison
BBIO vs TOL Comparison
Compare BBIO & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | TOL |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 14.0B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BBIO | TOL |
|---|---|---|
| Price | $69.21 | $140.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 17 |
| Target Price | $86.33 | ★ $164.44 |
| AVG Volume (30 Days) | ★ 2.3M | 840.6K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.19 |
| Revenue | $502,076,000.00 | ★ $7,143,258,000.00 |
| Revenue This Year | $89.45 | N/A |
| Revenue Next Year | $73.78 | $6.01 |
| P/E Ratio | ★ N/A | $64.89 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $31.77 | $100.92 |
| 52 Week High | $84.94 | $168.36 |
Technical Indicators
Market Signals| Indicator | BBIO | TOL |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 44.50 |
| Support Level | $61.95 | $133.98 |
| Resistance Level | $78.96 | $139.64 |
| Average True Range (ATR) | 3.93 | 3.86 |
| MACD | -0.87 | -0.35 |
| Stochastic Oscillator | 4.38 | 5.37 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About TOL Toll Brothers Inc.
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.